SWOG S0919: A Phase II Study of Idarubicin and Ara-C in Combination with Pravastatin for Relapsed Acute Myelogenous Leukemia
This is a clinical trial of Idarubicin and Ara-C that will be administered by IV which is standard of care and Pravastatin that will be administered by mouth and is investigational.
IRB Protocol #
EMILY DENONCOURT at (303)748-0566 or EMILY.DENONCOURT@UCDENVER.EDU
University of Colorado Hospital University of Colorado Hospital
Eligibility and Other Participant Information
What To Expect : A screening period to determine eligibility. A treatment period that can last up to 5 years. A follow up period will consist of clinic visits. // Eligibility criteria include but are not limited to 18 years or older with acute myelogenous leukemia.Eligibility criteria include but are not limited to 18 years or older with acute myelogenous leukemia.